MD Anderson Phase 2 Study Reveals Combo Chemo & Immunotherapy Effective in Leukemia

Nov 10, 2018 | Combination Therapy, Immunotherapy, Leukemia, MD Anderson, Oncology

As reported in Science Daily, a combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia, according to new findings.

Lead Research/Investigator

Naval Daver, M.D.

 

0 Comments

Pin It on Pinterest